The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Denzapine 50 mg/ml Oral Suspension

50 milligram(s)/millilitre Oral suspension

Clonmel Healthcare LtdPA0126/235/005

Main Information

Trade NameDenzapine 50 mg/ml Oral Suspension
Active SubstancesClozapine
Strength50 milligram(s)/millilitre
Dosage FormOral suspension
Licence HolderClonmel Healthcare Ltd
Licence NumberPA0126/235/005

Group Information

ATC CodeN05AH Diazepines, oxazepines, thiazepines and oxepines
N05AH02 clozapine

Status

Authorised/WithdrawnAuthorised
Licence Issued06/03/2009
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceDENZAPINE Official Recommendations: DENZAPINE is associated with a specific risk of agranulocytosis. Any adverse haematological effects should be notified to the Irish Medicines Board. Intrinsic to Denzapine therapy is enrolment with and monitoring by the DENZAPINE Monitoring Service (DMS), based at: Denzapine Monitoring Service Merz Pharma UK Ltd., 260 Centennial Park, Elstree South, Elstree, Hertfordshire WD6 3SR, UK. The DMS database embodies tightly controlled post-marketing surveillance and ensures the safe use of DENZAPINE in registered patients. Features of the DMS which are of fundamental importance to patient safety include the following: Psychiatrists who wish to prescribe DENZAPINE must be registered with the DMS. Pharmacists dispensing DENZAPINE must be registered with the DMS. Patients to receive DENZAPINE must be enrolled with the DMS. They must undergo pre-treatment screening, as well as subsequent haematological tests. These will be weekly initially, then may become fortnightly after a perio
Marketing StatusMarketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back